Multiple Myeloma Therapies Drive Rapid Market Growth

📢 Incyte Wins FDA Approval for JAKAFI XR 🔗 Read more: https://lnkd.in/g6Bn5ZnZ Incyte has secured FDA approval for #JAKAFI XR. This expands treatment options with a more convenient dosing approach. About the Company: • Global #biopharma company • Focus on #oncology & #inflammation • Strong commercial portfolio About JAKAFI XR: • Extended-release formulation • Targets #hematologic conditions • Improved dosing convenience Key Highlights: • FDA approval achieved • Expanded patient access • Strengthens product #lifecycle "Congratulations to Incyte." 🎉 Bill Meury, Pablo Cagnoni, Soni Basi, Ph.D., Steven Stein 🤝 “#Lifecycle management is how #pharma extends real value.” #Pharma #FDAApproval #Oncology #Innovation #Healthcare FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency American Society of Hematology American Society of Clinical Oncology (ASCO) The Leukemia & Lymphoma Society European Hematology Association (EHA) || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech ||

🎉 Excited to share that my latest research has been published in Life (MDPI), a Q1 journal! 📄 Title: "Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy" Glioblastoma multiforme (GBM) remains one of the deadliest brain tumors, with very limited treatment options. Our study explored whether resveratrol (RES) a natural polyphenol could offer therapeutic benefit in GBM, either alone or in combination with the targeted agents dabrafenib and trametinib. 🔬 Key findings: • In BRAFV600E mutant cells (LN428), neither RES nor D+T showed significant inhibitory effects, highlighting how mutational background governs treatment response. • Notably, D+T treatment induced upregulation of pSTAT3, which RES was able to reverse but only in wild-type cells. 💡 This work positions RES as a promising dual-pathway inhibitor and underscores the importance of mutation-stratified approaches in GBM therapeutics. 📖 Read the full paper here: https://lnkd.in/gNAhAwuZ #Glioblastoma #BrainCancer #CancerResearch #Resveratrol #MAPK #STAT3 #BRAF #Oncology #PublishedResearch #OpenAccess

NRG1 fusion-positive cholangiocarcinoma. Ultra-rare. Aggressive. Until May 8, 2026 there was no approved targeted therapy. That changed. Bizengri (zenocutuzumab-zbco) is now the first FDA-approved drug for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma who progressed on or after prior systemic therapy. The speed of this approval is worth noting. The Commissioner's National Priority Voucher (CNPV) was received on May 6. Approval came May 8 under a program designed to compress standard 10-12 month review timelines for rare diseases with genuine unmet need. This is the 7th approval under the CNPV pilot. Zenocutuzumab is a HER2/HER3 bispecific antibody. NRG1 fusions drive oncogenic signaling through HER3. The drug blocks that interaction preventing HER2/HER3 heterodimerization and downstream activation. Data: • Single-arm trial, 19 evaluable patients • ORR 36.8% • DOR 2.8 -12.9 months Small cohort expected in an ultra-rare indication but the signal is meaningful and consistent with what was seen in NSCLC and pancreatic adenocarcinoma, where Bizengri received accelerated approval. Safety to know: • Serious adverse events include infusion-related reactions, ILD/pneumonitis, and left ventricular dysfunction. Relevant for clinical monitoring conversations. NRG1 fusions are not reliably detected on DNA-only sequencing panels. RNA-based testing is essential. Without the right test, patients with this alteration will be missed entirely. Same mechanism. Third tumour type. The biology is consistent but the access to testing seems to be the bottleneck now. #Oncology #NRG1 #Zenocutuzumab #Bizengri #Cholangiocarcinoma #PrecisionMedicine #MedicalAffairs #ClinicalResearch

The siRNA field is advancing rapidly. In the past, RNAi therapeutics were mainly recognized for “gene silencing” itself; today, the industry focus is shifting toward longer-lasting efficacy, more precise delivery systems, and broader clinical translation. Over the past three months, we have seen several representative advances: for example, Zilebesiran continues to move forward in cardiovascular diseases, highlighting the potential of long-acting RNAi therapeutics in chronic disease management; Plozasiran received a positive CHMP opinion in Europe, further validating the clinical value of siRNA therapeutics in rare metabolic diseases. Meanwhile, siRNA delivery technologies are also making continuous progress, expanding from traditional liver-targeted GalNAc systems to broader application scenarios such as respiratory, muscle, and tumor delivery. At Bio-Bounce, we closely follow the latest trends in RNA therapeutics. From oligonucleotide monomers and GalNAc-related intermediates to purification and analytical solutions, we aim to support our partners with reliable supply chain resources and a strong understanding of frontier technologies, helping accelerate RNA therapeutics projects more efficiently. #siRNA #RNAi #Oligonucleotides #GalNAc #RNATherapeutics #BioBounce

𝘼 𝙨𝙞𝙜𝙣𝙞𝙛𝙞𝙘𝙖𝙣𝙩 𝙖𝙙𝙫𝙖𝙣𝙘𝙚𝙢𝙚𝙣𝙩 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙞𝙜𝙝𝙩 𝙖𝙜𝙖𝙞𝙣𝙨𝙩 𝘾𝙝𝙧𝙤𝙣𝙞𝙘 𝙃𝙚𝙥𝙖𝙩𝙞𝙩𝙞𝙨 𝘽 (𝘾𝙃𝘽) 𝙞𝙨 𝙤𝙣 𝙩𝙝𝙚 𝙝𝙤𝙧𝙞𝙯𝙤𝙣. GSK’s investigational therapy 𝐁𝐞𝐩𝐢𝐫𝐨𝐯𝐢𝐫𝐬𝐞𝐧 is currently undergoing priority regulatory review in Canada, following encouraging Phase III clinical trial outcomes demonstrating meaningful “functional cure” potential in CHB patients.  The therapy is also under regulatory review across multiple global regions including the US, Europe, Japan, and China. With more than 250 million people globally affected by Chronic Hepatitis B and the disease remaining a major contributor to cirrhosis and liver cancer, innovations like these represent a promising step toward transforming long-term HBV care beyond lifelong viral suppression. The 𝘾𝙚𝙣𝙩𝙧𝙚 𝙛𝙤𝙧 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 (𝘾𝘾𝙍) at John C. Martin Center for Liver Research and Innovations (JCMLRI), remains committed to advancing clinical research, supporting innovation-driven healthcare, and contributing to the evolving landscape of hepatology and liver disease management. The future of HBV therapeutics is steadily moving toward functional cure strategies — an encouraging development for clinicians, researchers, and patients worldwide. 🌍🔬 #CCRJCMLRI #ClinicalResearch #ChronicHepatitisB #LiverDisease #Hepatology #ClinicalTrials #TranslationalResearch #HealthcareInnovation #FunctionalCure #GlobalHealth #ResearchExcellence

🚨 FDA approves zenocutuzumab-zbco for advanced NRG1 fusion-positive cholangiocarcinoma https://lnkd.in/gmRvuBug On May 8, 2026, the U.S. FDA approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion, after progression on or after prior systemic therapy. The approval was supported by eNRGy (NCT02912949), a multicenter, open-label, multi-cohort trial. Among 19 efficacy-evaluable patients: • Confirmed ORR: 36.8% • 95% CI: 16.3–61.6 • Duration of response: 2.8 to 12.9 months The recommended dose is 750 mg IV every 2 weeks until disease progression or unacceptable toxicity. The application was granted priority review, and zenocutuzumab-zbco received breakthrough designation and orphan drug designation. #Oncology #GIcancer #Cholangiocarcinoma #NRG1 #FDA #BiliaryTractCancer #PrecisionMedicine #Zenocutuzumab   Alison Schram Teresa Macarulla Antoine Hollebecque Hong Sai Jordi Rodón, Michael Duruisseaux Joon Oh Park, Cindy NEUZILLET Stephen Liu, Benjamin Weinberg James Cleary, Emiliano Calvo Aller Misako Nagasaka,  Christoph Springfeld, Tanios Bekaii-Saab, Grainne O'Kane MB, BCH, BAO, MRCPI, MD, Frans Opdam, Ernesto Wasserman, Shekeab Jauhari, Alexander Drilon

Genentech and Natera just made MRD a treatment gate in bladder cancer. That is more important than another precision oncology headline. FDA approved Tecentriq and Tecentriq Hybreza as adjuvant treatments for adults with muscle-invasive bladder cancer after cystectomy who have ctDNA molecular residual disease, as determined by an FDA-authorized test. FDA also approved Signatera CDx as the companion diagnostic to select those patients. In IMvigor011, FDA reported median disease-free survival of 9.9 months with atezolizumab versus 4.8 months with placebo, and median overall survival of 32.8 months versus 21.1 months. Genentech described this as the first approved ctDNA MRD-guided therapy. My view: the real signal is not the assay or the drug alone. It is the operating model they create together. This is where precision medicine becomes workflow. Someone has to own serial testing, timing after cystectomy, result routing, treatment escalation, patient counseling, documentation, payer logic, and evidence monitoring. In real deployments, the fragile point is rarely the biomarker. It is whether the next clinical action is unambiguous, reimbursable, timely, and owned. How should health systems and diagnostics companies design the operating layer around MRD-guided treatment? #precisionmedicine #companiondiagnostics #liquidbiopsy #mrd #oncology #diagnostics #genomics #biotech #pharma #clinicalworkflows #regulatorystrategy #reimbursement #futureofmedicine

🚨 Big moment in oncology & drug innovation The FDA has approved vepdegestrant (Veppanu), the first-ever PROTAC (protein degrader) therapy for a subset of breast cancer patients. This isn’t just another drug approval. It represents a new way of targeting disease. Request a sample here: https://lnkd.in/d845CvYX⁠� What makes this different? Traditional therapies block proteins. PROTACs eliminate them. That shift from inhibition to degradation could reshape how we approach not just cancer, but multiple diseases driven by problematic proteins. Key clinical takeaways (VERITAC-2 trial): 43% reduction in risk of progression or death (vs fulvestrant) Median PFS: 5.0 vs 2.1 months Response rate: 19% vs 4% But here’s the nuance that matters: The benefit is specific to ESR1-mutated patients No statistically significant PFS benefit in the overall population 👉 Translation: this is a precision medicine win, not a universal breakthrough. 💡 Why this matters beyond this drug: Validates PROTACs as a real therapeutic class. Tackles endocrine resistance — a major challenge in ER+ breast cancer. Opens the door for a new wave of “undruggable” targets The gains are measured in months, not years — so expectations should stay grounded. But scientifically? This is a big step forward. Curious to see how fast protein degraders expand into other indications. #Oncology #Biotech #Pharma #PrecisionMedicine #DrugDiscovery #BreastCancer

🚀 Systemic Sclerosis Pipeline Heats Up: Next-Generation Therapies Redefining Treatment Landscape The #SystemicSclerosisTherapeutic landscape is witnessing remarkable progress, with leading biopharmaceutical companies and research institutions advancing innovative therapies aimed at transforming patient outcomes. Recent developments highlighted in #DelveInsight's latest Systemic Sclerosis Pipeline Insight underscore the growing momentum in this challenging autoimmune disease space:- 🔬 On March 31, 2026, Galderma initiated a clinical study evaluating Nemolizumab in adult patients with systemic sclerosis. The trial will assess its efficacy in improving cutaneous thickness and safety over a 52-week treatment period while identifying the optimal dose for this patient population. 🧬 On March 27, 2026, Hospital for Special Surgery launched a study exploring the combination of Belimumab and Rituximab in patients receiving background mycophenolate mofetil (MMF), potentially paving the way for enhanced combination treatment strategies. 💡 Also on March 27, 2026, Nkarta, Inc. initiated a Phase I/II basket study of NKX019, an allogeneic CAR NK cell therapy targeting CD19, for autoimmune diseases, signaling the expansion of cell therapy into autoimmune indications. 🏥 On March 24, 2026, UMC Utrecht announced a pivotal trial comparing upfront autologous HSCT with standard-of-care treatment, including cyclophosphamide and MMF, in systemic sclerosis management. 📈 Discover comprehensive pipeline insights, emerging therapies, #SystemicSclerosisClinicalTrial developments @ https://lnkd.in/eCe5aF3w #SystemicSclerosis #SystemicSclerosisPipeline #AutoimmuneDiseases #DrugDevelopment #Biotech #Pharma #ClinicalTrials #CellTherapy #Immunology #DelveInsight #Healthcare #PharmaceuticalIndustry #MarketResearch #EmergingTherapies #RareDiseases

📢 Pierre Fabre Laboratories Advances FDA Path for Tabelecleucel 🔗 Read more: https://lnkd.in/gBnqKV_N Promising momentum in cell therapy and oncology innovation. Pierre Fabre Laboratories is advancing the FDA regulatory pathway for tabelecleucel, supporting continued progress in next-generation cancer therapies. About the Company: • Global pharmaceutical and healthcare company • Focused on #oncology and specialty care • Advancing innovative cell therapy solutions Key Highlights: • Progress in FDA regulatory pathway • Advances oncology treatment development • Supports cell therapy innovation Cell therapies continue showing significant potential in addressing complex cancers and improving treatment outcomes. 👏 Congratulations to the Pierre Fabre Laboratories team on this progress. Roch Doliveux, Marie-Anne Aymerich, Jean-Laurent Bonnafé, Isabelle Girolami, Herve Hoppenot, Marie-France Marchand-Baylet, Rachel Marouani 🤝 “Regulatory advancement remains critical in bringing innovative therapies to patients.” #Biotech #CellTherapy #Oncology #FDA #DrugDevelopment #CancerResearch #HealthcareInnovation FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency American Society of Hematology AMERICAN SOCIETY FOR RECONSTRUCTIVE TRANSPLANTATION Alliance for Regenerative Medicine European Hematology Association (EHA) Biotechnology Innovation Organization || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech ||